Neutralization titers against ZIKV and DENV.

Alba Grifoni (3137199); Alessandro Sette (19132); Aline Domingues (4102369); Cassia G. T. Silveira (4102372); Daniela Weiskopf (476163); David I. Watkins (36142); Diogo M. Magnani (4102390); Esper G. Kallas (36139); Helen S. Maxwell (4102396); Hyeryun Choe (233654); John Altman (4710032); John Pham (4710034); Karthik Gangavarapu (4710035); Kristian G. Andersen (225212); Lucas Gonzalez-Nieto (4102363); Mario Stevenson (45222); Mark Sharkey (45221); Martin J. Gutman (4102366); Mauricio A. Martins (102761); Michael J. Ricciardi (4102375); Nathan D. Grubaugh (446564); Núria Pedreño-Lopez (4102378); Paola Lichtenberger (4710033); Stephen S. Whitehead (150702); Varian K. Bailey (4102360); Young-Chan Kwon (4710036)

Abstract

(A) Neutralization titers were performed by flow cytometry at several time points against ZIKV-Paraiba/2015 and the NEUT50 was calculated based on a non-linear regression. Peak NEUT50 occurred at D15 POS. Hu0002 was used as a flavivirus-naïve control and Hu0004 was a DENV- and ZIKV-exposed control. (B) Plaque reduction neutralization tests (PRNTs) were also performed against ZIKV and all four DENV serotypes. PRNT50 was calculated as 50% neutralization of plaques based on control virus wells and reported as a dilution of patient plasma. (N/A = samples not run).</p

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/57272...

Last time updated on 12/02/2018